Fucan Purification via Selective Endotoxin Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for separating endotoxins from fucan compositions are inefficient due to interference from sulfate groups and often result in degradation of fucans, leading to unsuitable fucan compositions for medical and surgical applications.
Innovation Solution
Development of fucan-low endotoxin compositions with reduced endotoxin levels, achieved through methods such as tangential flow filtration, anion-exchange with macroporous resins, and chemical treatments that minimize fucan degradation, allowing for the creation of fucan compositions suitable for medical and surgical use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional endotoxin separation methods are used, then endotoxin removal is achieved, but fucan degradation occurs and sulfate groups interfere with separation
Solution Approach 1:
The patent extracts endotoxins from fucan compositions using selective binding agents that specifically target endotoxin molecules. The binding agents (such as polymyxin B, edaravone, or other selective binders) are introduced to the fucan mixture, where they selectively bind to endotoxin molecules, allowing the endotoxin-bound complexes to be separated from the intact fucan molecules through filtration or centrifugation. This extraction approach removes the harmful endotoxin component without degrading the fucan structure.
Solution Approach 2:
The patent introduces intermediary substances (selective binding agents) that mediate between the endotoxin and the separation process. These intermediaries include polymyxin B, edaravone, or other compounds that specifically bind to endotoxin but do not interact with fucan molecules. The binding agents act as mediators that facilitate endotoxin removal while leaving the fucan composition intact, solving the problem of direct separation methods causing fucan degradation.
2Object-affected harmful factors
If chemical treatments are applied to remove endotoxins, then endotoxin levels are reduced, but fucan molecules are degraded
Solution Approach 1:
The patent replaces chemical treatment methods with physical separation mechanisms. Instead of using chemical reagents that react with and potentially degrade fucan molecules, the invention uses physical processes such as selective binding followed by filtration or centrifugation. The binding agents physically attach to endotoxin molecules, and the complexes are removed through mechanical separation techniques, avoiding chemical degradation of the fucan composition while achieving endotoxin removal.
3Object-affected harmful factors
If endotoxin removal methods are applied, then endotoxin levels decrease, but the process complexity increases due to sulfate group interference
Solution Approach 1:
The patent changes the binding parameters of the separation system by introducing selective binding agents with specific affinity for endotoxin molecules. The binding agents are chosen or designed to have high selectivity for endotoxin over fucan sulfate groups, changing the interaction parameters of the system. This allows endotoxin removal without the need for complex multi-step purification processes, as the selective binding occurs under mild conditions that do not require complex equipment or multiple processing stages.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting fucan-low endotoxin compositions achieve significant reductions in endotoxin levels, reducing complications like inflammation and fever, and are suitable for medical and surgical applications, with endotoxin levels reduced by up to 99.99999%.
Implementation Method 1
anion-exchange with macroporous resins
Implementation Method 2
tangential flow filtration
Data Source
AI summary
Fucan-low endotoxin compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising less than about 0.2. 0.18. 0.1. 0.01. 0.001. or 0.0005 endotoxin units (EU) per milligram of the fucan.